Sutro Historical Balance Sheet

STRO Stock

USD 0.76 0.01 1.29%

Trend analysis of Sutro Biopharma balance sheet accounts such as Other Liabilities of 108.7 M, Net Tangible Assets of 130.6 M, Property Plant And Equipment Net of 30.5 M or Current Deferred Revenue of 38.2 M provides information on Sutro Biopharma's total assets, liabilities, and equity, which is the actual value of Sutro Biopharma to its prevalent stockholders. By breaking down trends over time using Sutro Biopharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Sutro Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sutro Biopharma is a good buy for the upcoming year.

Sutro Biopharma Inventory

0.95

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.

About Sutro Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Sutro Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Sutro Biopharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Sutro Biopharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Sutro currently owns. An asset can also be divided into two categories, current and non-current.

Sutro Biopharma Balance Sheet Chart

At this time, Sutro Biopharma's Short Term Investments are very stable compared to the past year. As of the 25th of March 2025, Capital Surpluse is likely to grow to about 707.9 M, while Total Assets are likely to drop about 304.3 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Sutro Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Sutro Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Sutro Biopharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Sutro Biopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Sutro Biopharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Sutro Biopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.At this time, Sutro Biopharma's Short Term Investments are very stable compared to the past year. As of the 25th of March 2025, Capital Surpluse is likely to grow to about 707.9 M, while Total Assets are likely to drop about 304.3 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	23.3M	38.0M	44.1M	46.3M
Total Assets	406.9M	470.7M	387.2M	304.3M

Other Current Liab Total Assets

Sutro Biopharma balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab
Total Assets		0.76	0.58	0.86	0.71	0.95	0.69	0.1	-0.46	-0.79	0.8	0.67	0.62	0.69	0.27	0.55	0.98	0.74	0.84	0.92	0.94	0.12	0.95	0.76	0.95	0.34
Other Current Liab	0.76		0.71	0.39	0.92	0.63	0.69	0.21	-0.45	-0.98	0.84	0.61	0.53	0.64	0.13	0.03	0.71	0.69	0.96	0.69	0.6	0.46	0.84	0.96	0.8	0.64
Total Current Liabilities	0.58	0.71		0.2	0.8	0.4	0.71	0.78	-0.14	-0.73	0.61	0.29	0.48	0.88	-0.13	-0.26	0.54	0.4	0.68	0.62	0.4	0.47	0.54	0.72	0.66	0.77
Total Stockholder Equity	0.86	0.39	0.2		0.33	0.94	0.46	-0.13	-0.34	-0.44	0.49	0.54	0.58	0.49	0.42	0.84	0.85	0.51	0.55	0.79	0.93	-0.37	0.81	0.44	0.77	-0.18
Other Liab	0.71	0.92	0.8	0.33		0.56	0.55	0.43	-0.49	-0.91	0.7	0.62	0.35	0.76	-0.19	-0.08	0.71	0.57	0.85	0.68	0.54	0.43	0.75	0.89	0.71	0.66
Net Tangible Assets	0.95	0.63	0.4	0.94	0.56		0.54	-0.03	-0.52	-0.69	0.73	0.7	0.57	0.59	0.35	0.74	0.94	0.6	0.76	0.82	0.99	-0.1	0.94	0.68	0.91	0.1
Property Plant And Equipment Net	0.69	0.69	0.71	0.46	0.55	0.54		0.35	0.12	-0.66	0.59	0.13	0.9	0.69	0.53	0.04	0.56	0.63	0.71	0.76	0.5	0.26	0.66	0.65	0.73	0.49
Current Deferred Revenue	0.1	0.21	0.78	-0.13	0.43	-0.03	0.35		0.07	-0.26	0.06	-0.01	0.2	0.7	-0.35	-0.45	0.09	-0.18	0.21	0.2	-0.02	0.16	0.08	0.31	0.18	0.45
Net Debt	-0.46	-0.45	-0.14	-0.34	-0.49	-0.52	0.12	0.07		0.54	-0.45	-0.96	0.22	-0.13	0.25	-0.43	-0.58	-0.11	-0.49	-0.17	-0.57	-0.15	-0.54	-0.52	-0.41	-0.17
Retained Earnings	-0.79	-0.98	-0.73	-0.44	-0.91	-0.69	-0.66	-0.26	0.54		-0.86	-0.69	-0.51	-0.68	-0.1	-0.12	-0.76	-0.62	-0.98	-0.69	-0.67	-0.42	-0.88	-0.99	-0.85	-0.61
Accounts Payable	0.8	0.84	0.61	0.49	0.7	0.73	0.59	0.06	-0.45	-0.86		0.56	0.41	0.49	0.16	0.24	0.78	0.76	0.87	0.68	0.72	0.52	0.8	0.79	0.88	0.64
Cash	0.67	0.61	0.29	0.54	0.62	0.7	0.13	-0.01	-0.96	-0.69	0.56		0.06	0.35	-0.08	0.52	0.75	0.26	0.68	0.4	0.74	0.1	0.74	0.69	0.61	0.19
Non Current Assets Total	0.62	0.53	0.48	0.58	0.35	0.57	0.9	0.2	0.22	-0.51	0.41	0.06		0.62	0.74	0.25	0.46	0.45	0.6	0.67	0.51	-0.13	0.64	0.56	0.66	0.11
Non Currrent Assets Other	0.69	0.64	0.88	0.49	0.76	0.59	0.69	0.7	-0.13	-0.68	0.49	0.35	0.62		-0.02	0.04	0.65	0.34	0.67	0.74	0.58	0.05	0.68	0.71	0.73	0.42
Other Assets	0.27	0.13	-0.13	0.42	-0.19	0.35	0.53	-0.35	0.25	-0.1	0.16	-0.08	0.74	-0.02		0.44	0.12	0.21	0.21	0.21	0.28	-0.27	0.32	0.13	0.3	-0.25
Long Term Debt	0.55	0.03	-0.26	0.84	-0.08	0.74	0.04	-0.45	-0.43	-0.12	0.24	0.52	0.25	0.04	0.44		0.58	0.18	0.24	0.37	0.76	-0.53	0.54	0.13	0.46	-0.49
Cash And Short Term Investments	0.98	0.71	0.54	0.85	0.71	0.94	0.56	0.09	-0.58	-0.76	0.78	0.75	0.46	0.65	0.12	0.58		0.7	0.8	0.88	0.95	0.12	0.92	0.72	0.91	0.32
Net Receivables	0.74	0.69	0.4	0.51	0.57	0.6	0.63	-0.18	-0.11	-0.62	0.76	0.26	0.45	0.34	0.21	0.18	0.7		0.66	0.81	0.57	0.46	0.65	0.52	0.7	0.5
Common Stock Shares Outstanding	0.84	0.96	0.68	0.55	0.85	0.76	0.71	0.21	-0.49	-0.98	0.87	0.68	0.6	0.67	0.21	0.24	0.8	0.66		0.76	0.74	0.31	0.93	0.97	0.9	0.52
Short Term Investments	0.92	0.69	0.62	0.79	0.68	0.82	0.76	0.2	-0.17	-0.69	0.68	0.4	0.67	0.74	0.21	0.37	0.88	0.81	0.76		0.79	0.08	0.84	0.66	0.87	0.32
Long Term Debt Total	0.94	0.6	0.4	0.93	0.54	0.99	0.5	-0.02	-0.57	-0.67	0.72	0.74	0.51	0.58	0.28	0.76	0.95	0.57	0.74	0.79		-0.08	0.92	0.66	0.91	0.11
Non Current Liabilities Total	0.12	0.46	0.47	-0.37	0.43	-0.1	0.26	0.16	-0.15	-0.42	0.52	0.1	-0.13	0.05	-0.27	-0.53	0.12	0.46	0.31	0.08	-0.08		0.04	0.3	0.18	0.93
Capital Surpluse	0.95	0.84	0.54	0.81	0.75	0.94	0.66	0.08	-0.54	-0.88	0.8	0.74	0.64	0.68	0.32	0.54	0.92	0.65	0.93	0.84	0.92	0.04		0.88	0.94	0.27
Other Current Assets	0.76	0.96	0.72	0.44	0.89	0.68	0.65	0.31	-0.52	-0.99	0.79	0.69	0.56	0.71	0.13	0.13	0.72	0.52	0.97	0.66	0.66	0.3	0.88		0.83	0.53
Other Stockholder Equity	0.95	0.8	0.66	0.77	0.71	0.91	0.73	0.18	-0.41	-0.85	0.88	0.61	0.66	0.73	0.3	0.46	0.91	0.7	0.9	0.87	0.91	0.18	0.94	0.83		0.42
Total Liab	0.34	0.64	0.77	-0.18	0.66	0.1	0.49	0.45	-0.17	-0.61	0.64	0.19	0.11	0.42	-0.25	-0.49	0.32	0.5	0.52	0.32	0.11	0.93	0.27	0.53	0.42

Click cells to compare fundamentals

Sutro Biopharma Account Relationship Matchups

Sutro Biopharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	394.1M	341.4M	406.9M	470.7M	387.2M	304.3M
Other Current Liab	627K	18.8M	23.3M	38.0M	44.1M	46.3M
Total Current Liabilities	29.6M	41.7M	139.5M	93.7M	131.9M	71.9M
Total Stockholder Equity	332.0M	252.6M	217.0M	149.6M	44.6M	42.4M
Other Liab	16.7M	7.9M	146K	90.0M	103.5M	108.7M
Net Tangible Assets	97.8M	332.0M	252.6M	217.0M	249.6M	130.6M
Property Plant And Equipment Net	12.9M	51.6M	51.1M	44.8M	35.9M	30.5M
Current Deferred Revenue	14.6M	5.5M	106.6M	20.7M	69.8M	38.2M
Net Debt	(181.6M)	27.0M	20.3M	(35.6M)	(167.2M)	(158.8M)
Retained Earnings	(227.9M)	(333.4M)	(452.6M)	(559.4M)	(786.9M)	(747.5M)
Accounts Payable	5.5M	6.0M	4.8M	9.4M	10.5M	6.3M
Cash	206.2M	30.4M	47.3M	69.3M	190.3M	199.8M
Non Current Assets Total	15.9M	122.9M	97.5M	49.2M	43.9M	49.5M
Non Currrent Assets Other	2.1M	2.5M	14.4M	4.4M	8.0M	4.7M
Other Assets	2.6M	3.0M	122.9M	2.7M	3.1M	3.0M
Long Term Debt	8.9M	24.5M	15.7M	3.8M	4.3M	4.1M
Cash And Short Term Investments	368.1M	197.9M	302.3M	375.6M	316.9M	238.7M
Net Receivables	5.6M	12.5M	7.1M	36.1M	8.6M	9.9M
Common Stock Shares Outstanding	32.6M	46.1M	50.7M	60.2M	76.8M	80.7M
Short Term Investments	162.0M	167.5M	287.1M	306.4M	126.6M	156.1M
Long Term Debt Total	10M	8.9M	24.5M	15.7M	18.1M	11.4M
Liabilities And Stockholders Equity	394.1M	341.4M	406.9M	470.7M	387.2M	304.3M
Non Current Liabilities Total	32.5M	47.1M	50.4M	227.3M	210.7M	107.1M
Capital Surpluse	281.9M	293.3M	559.7M	586.2M	674.2M	707.9M
Other Current Assets	4.5M	8.1M	11.7M	9.8M	17.8M	18.7M
Other Stockholder Equity	559.7M	586.2M	670.2M	709.0M	831.3M	454.6M
Total Liab	62.1M	88.8M	189.9M	321.1M	342.6M	179.0M
Property Plant And Equipment Gross	12.9M	85.0M	51.1M	86.9M	84.5M	45.7M
Total Current Assets	378.2M	218.5M	309.5M	421.5M	343.3M	254.8M
Accumulated Other Comprehensive Income	129K	(314K)	(618K)	21K	39K	41.0K
Non Current Liabilities Other	481K	146K	119K	1.7M	1.9M	2.0M
Short Term Debt	8.8M	11.4M	21.7M	10.5M	7.5M	10.2M
Property Plant Equipment	9.6M	12.9M	51.6M	51.1M	58.7M	61.7M
Short Long Term Debt Total	33.4M	57.4M	67.5M	33.6M	23.2M	35.2M
Net Invested Capital	356.6M	277.7M	233.3M	153.7M	44.6M	42.4M
Net Working Capital	348.6M	176.8M	286.6M	327.8M	211.4M	221.9M

Pair Trading with Sutro Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Sutro Stock

0.78

CDIOW

Cardio Diagnostics

Pair Corr

Moving against Sutro Stock

0.69	LUCD	Lucid Diagnostics	Pair Corr
0.55	WM	Waste Management	Pair Corr
0.39	GE	GE Aerospace	Pair Corr
0.34	PG	Procter Gamble	Pair Corr

The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.

The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Sutro Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sutro Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sutro Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sutro Biopharma Stock:

How To Invest In Sutro

Details

Is Sutro Stock a good investment?

Details

What is Sutro Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.96)

Revenue Per Share

0.808

Quarterly Revenue Growth

(0.87)

Return On Assets

(0.35)

Return On Equity

(2.34)

The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sutro Historical Balance Sheet

Sutro Biopharma Inventory

0.95

About Sutro Balance Sheet Analysis

Sutro Biopharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Sutro Biopharma balance sheet Correlations

Sutro Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sutro Biopharma balance sheet Accounts

Pair Trading with Sutro Biopharma

Moving together with Sutro Stock

Moving against Sutro Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Long Term Debt Total	+ 0.99	Net Tangible Assets
Cash And Short Term Investments	+ 0.98	Total Assets
Other Current Assets	+ 0.97	Common Stock Shares Outstanding
Common Stock Shares Outstanding	+ 0.96	Other Current Liab
Other Current Assets	+ 0.96	Other Current Liab
Net Tangible Assets	+ 0.95	Total Assets

Other Current Assets	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Other Current Liab
Cash	- 0.96	Net Debt
Retained Earnings	- 0.91	Other Liab
Capital Surpluse	- 0.88	Retained Earnings